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Fibronectin (FN) 1 is a high molecular weight glycoprotein found in the plasma 
and  intracellular  matrix  which  participates  in  reticuloendothelial  clearance  of 
particles and helps to maintain vascular stability (1). Recently, FN has been shown 
to  promote  the attachment  of immunogiobulin-coated  erythrocytes to  human 
mononuclear phagocytes (2). This effect has been postulated (3) to be due to an 
effect of FN on the number or location of Ig Fc receptors on the surface of the 
phagocytic  cells.  In  the  present  studies,  we  have  examined  the  interaction 
between FN, monoclonal and polycional antibody, and a  major bacterial patho- 
gen,  group  B  streptococci,  in  both  opsonic  and  protective  assays.  The  data 
suggest  that  this  high  molecular  weight  glycoprotein  has  an  additive  or  even 
synergistic effect with these Ig preparations in promoting both bacterial uptake 
and protection. 
Materials and Methods 
Preparation of Organisms.  Human isolates of group B streptococci were cultured in 
Todd Hewitt broth (Difco Laboratories Inc., Detroit, MI) at 37°C for 16 h. The organisms 
were washed three times in sterile phosphate-buffered saline (PBS)  (4,500 ml distilled 
water, 5.2 g Na2HPO4, 0.9 g KCI, 0.9 g KH2PO4,  36 g NaCi) and adjusted to an optical 
density of 0.9 at a wavelength of 620 nm (Spectronic 20; Bausch & Lomb Inc., Rochester, 
NY). These standard suspensions contained ~5.0 ×  108 colony-forming  units per milliliter. 
Organisms were also grown overnight in the presence of tritiated thymidine (5 #Ci/ml) 
for use in the radiolabeled bacterial uptake experiments. 
Preparation  of Polymorphonuclear Leukocytes.  Human  polymorphonuclear leukocyte 
(PMN)  suspensions  were  prepared  from  heparinized  (10  U/ml)  whole  blood.  After 
sedimentation of the erythrocytes, the leukocyte-rich  plasma was removed and centrifuged 
and the leukocyte button was washed twice in PBS. The cells were then resuspended in a 
final concentration of 1 X 107 PMN/ml. 
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Opsonization  Procedure.  Opsonization  of organisms  was  carried  out  at  37°C  with 
rotation in the presence of a  human polyclonal Ig modified for intravenous use (IgIV) 
(Cutter Laboratories, Inc.) or murine monocional antibody prepared as described below. 
Preparation  of the FN.  FN  was  prepared at  Cutter  Biologicals by modifications of 
previously described procedures (4).  Cryoprecipitate was  removed from fresh  frozen 
plasma and solubilized in distilled water at 20°C. Acidification to pH 6.5 was carried out 
and then the solution was chilled to 5°C. The chilled precipitate was then solubilized in 
PBS  and  contacted  with  gelatin-coated  Sepharose  (3,  4).  Unabsorbed  proteins  were 
removed  with  1  M  urea  and  the  FN  subsequently  eluted  with  4  M  urea.  Dialysis, 
uitrafiltration, and pasteurization at 60°C for 10 h were then carried out. Immunoelec- 
trophoretic analysis  of the preparation revealed no contamination with gamma globulin 
or complement and a  single precipitin arc with anti-FN and anti-whole human serum 
antibody (Cappel Laboratories, West Chester, PA). 
IgIV.  IgIV was obtained from Cutter Biologicalsand was prepared from Cohn fraction 
II of human plasma by previously described methods (5).  The IgIV contains antibody 
against the type-specific antigen of type IIl group B streptococci (6). 
Murine Type-specific Monoclonal Antibodies.  Murine monociona] antibodies of IgM (6), 
IgG, and IgA (7) isotype were prepared as previously described. Briefly, spleen cells from 
mice immunized with whole type III group B streptococci were fused with either murine 
myeloma SP 2/0 myeloma cells (IgM) or Ag 8.653 cells (IgG and IgA) using polyethylene 
glycol (PEG) (Sigma Chemical Co., St. Louis, MO). The cells were then cultured in media 
containing hypoxanthine, aminopterin,  and  thymidine  (HAT).  Supernatant  fluid  was 
screened for type-specific antibody using enzyme-linked immunosorbent assay (ELISA) 
methods previously described (6, 7). Positive cultures were cloned by limiting dilution in 
media without aminopterin. Isotypes of the clones were determined by double diffusion 
in  1%  agarose against  isotype-specific goat anti-mouse  Ig (Cappel  Laboratories, West 
Chester, PA and Litton Bionetics Inc., Kensington, MD). Cells were frozen for future use 
in liquid nitrogen. To produce high-titered antibody, ~5  ×  108 of the fused cells were 
injected intraperitoneally into BALB/c mice that had received 0.3 ml of tetramethylpen- 
tadecane 2-8 wk previously. 
Opsonic Assays.  Three assays of opsonic activity were used including a chemilumines- 
cence (CL) procedure (8), one dependent on the use of radiolabeled bacteria (9), and light 
and electron microscopy. In the CL assay, 0.5 ml of the bacterial suspension containing 
~5 ×  l0  s organisms was added to 0.5 ml of the cell suspension containing 5 X 108 PMN 
in  10 -6  M  luminol (Sigma Chemical Co.).  The mixtures were immediately placed in a 
Beckman LS 8000 scintillation counter (Beckman Instruments, Inc., Fuilerton, CA) and 
counted at 10-15-min intervals for up to 180 min. CL was expressed in cpm over time or 
as the area under the resulting curves (integrals) as calculated using Simpson's approxi- 
mation. 
Radiolabeled bacterial uptake experiments were carried out using PMN monolayers 
(>95%  PMN)  prepared  on  18  X  18-mm  glass  coverslips as  previously described (9). 
Bacteria  (0.3  ml  containing  5  X  108  organisms)  were added  to  the  monolayers and 
incubated for 30, 60, or 120 min at 37°C. The coverslips were then vigorously washed 
to remove all attached but uningested microorganisms (as determined by light and electron 
•  nicroscopy) and placed into Poly Q  scintillation vials (Beckman Instruments, Inc.) con- 
mining  Aquasol  (New  England  Nuclear,  Boston,  MA).  The  preparations  were  then 
counted in a scintillation counter and the percentage of ingested organisms determined. 
Giemsa-stained smears of coverslips were also examined by light microscopy in an attempt 
to differentiate ingested from attached organisms.  Selected phagocytic mixtures were 
fixed and examined by electron microscopy using standard fixing and staining techniques 
(10, 1 1). 
Determination of  Fc and C  3b Receptors on PMN.  IgG- and IgM-coated sheep erythrocytes 
(SE) were prepared as described by Bianco (12). IgM-C3b-coated cells were prepared as 
described by Newman, Musson, and Henson (13) using whole human complement that 
had been absorbed with SE and zymosan. A 2% solution of the antibody-coated SE was 
incubated with an equal volume of a PMN solution containing 1 X 107 PMN for a total 1620  FIBRONECTIN  ENHANCES  GROUP  B  STREPTOCOCCAL  ANTIBODY 
of 30 min after centrifugation. The percentage of PMN forming rosettes with three or 
more SE and the average number of SE attached to each PMN were then determined. 
Neonatal Rat Model,  The animal model used to determine the protective efficacy of 
the various preparations consisted of outbred Sprague-Dawley rats that were infected at 
<24 h of age as described previously (6). Briefly, ~5 x  10  ~ type III group B streptococci 
in a  10-p| vol were injected intraperitoneally. Animals also received a  separate intraperi- 
toneal  injection  (20  pl)  of the  antibody  and/or  the  FN,  Animals  were  observed  for 
mortality for at least 1 wk, 
Statistical  Analysis.  The  significance of differences between  survival  values  in  the 
animal experiments was determined by the chi-square test with Yates correction. 
Results 
FN had an effect to markedly enhance the uptake of antibody-coated group B 
streptococci. As shown in Fig. 1, type III group B streptococci opsonized in the 
human IgIV promoted a significant, early peak in PMN CL generation (180 X 
l0 s  cpm).  In  contrast,  FN  and  group  B  streptococci elicited only a  modest 
increase in  PMN  light production  after  100  rain.  When  FN  was added  to  a 
mixture of PMN and group B streptococci that were preopsonized in  IgIV, a 
marked  enhancement in  CL  generation  was  observed.  The  effect of FN  to 
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FIGURE  1.  Opsonic activity of FN and  IglV for type III group B  streptococci (GBS) as 
measured by PMN CL. HILL  ET  AL.  1621 
enhance CL generation by PMN exposed to IgIV-coated streptococci was some- 
what dose dependent, with the maximum effect occurring at physiologic concen- 
trations from 100 to 300 #g/ml (data not shown). Experiments were next carried 
out to determine if FN was acting on the organisms or on the PMN in the CL 
assay. The addition of FN to the preopsonization mixture containing group B 
streptococci and IgIV, followed by washing before the addition of PMN, had the 
effect of mildly enhancing CL generation (data not shown). In contrast, prein- 
cubation  of  PMN  suspensions  with  the  FN  followed  by  washing  markedly 
increased the response to IgIV-coated streptococci (Fig. 2). The most prominent 
response always occurred, however, when the FN was present in the final reaction 
mixture (Fig.  1). 
To verify the results of the CL assay of opsonization, we used a radiolabeled 
bacterial uptake technique (9).  In three separate experiments, IgIV promoted 
the uptake of an average of 36.7  _+ 6.4% of the radiolabeled type III group B 
streptococci  by  PMN  monolayers.  FN  alone,  in  contrast,  did  not  promote 
significant uptake of the organisms by the PMN (1.3 +  2.3%). When organisms 
were preopsonized in IgIV and then exposed to PMN monolayers to which FN 
had been added, an average of 56.3 _+ 12.7% of the bacteria were phagocytized. 
We next used rosetting techniques to determine if FN had an effect on Ig or 
complement receptors on human PMN. Preincubation of PMN with FN (100- 
300  #g/ml) for  1 h  slightly decreased the percentage of cells forming rosettes 
with IgG-coated SE (74.1 _+ 6.4% untreated to 56.1 +_ 8.1% with FN). Essentially 
no effect was observed on the expression of Fc receptors for IgM (0-3.0 _+ 5.2%) 
or C3b receptors (48.7  +  16.0 to 51.2  +  15.8%), however. There was also no 
effect of FN to increase the average number of SE attached to each PMN with 
any of the indicator cells. 
We next examined the opsonic effects of FN in combination with the three 
type-specific monoclonal antibody preparations.  As can be seen in Table I, the 
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FIGURE 2.  Effect of FN  preincubation  with  PMN  (FN-PMN)  on  CL  induced  by  IglV- 
opsonized group B streptococci. TABLE  I 
Effect of FN on the Opsonic Activity of Monoclonal  Type-specific 
Antibody Against Type III Group B Streptococci as Measured by 
PMN CL 
O.psonic  Peak CL  Integral* 
mixture  (cpm x  10  s)  (cpm x  103) 
Media alone  1.0  88 
FN alone  0.4  54 
IgG  40.1  5,741 
IgG +  FN  118.4  11,498 
lgM  10.0  1,367 
lgM +  FN  54.4  6,034 
IgA  39.5  6,046 
IgA +  FN  I68.6  22,253 
Mixtures contained  5  X  10 s organisms and  5  x  10  ~ PMN in  10 -6 M 
luminol. 
* Calculated area  under  the CL curve using Simpson's approximation. 
FN, I00 tzg/ml; IgG, 90 #g/ml; IgA, 90 pg/ml; IgM, 9 #g/ml. 
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FIGURE 3.  Effect of FN and  monoclonal IgG type-specific antibody administration on the 
survival of neonatal rats infected with type III group B streptococci (GBS). Rats received 5 x 
106 streptococci, 1,2 mg/kg of IgG monoclonal antibody, and/or 5 mg/kg of FN. 
IgG,  IgM, and IgA monoclonal antibody preparations produced at least some 
increase in PMN CL generation when used alone to opsonize group B strepto- 
cocci.  In contrast, the FN alone failed to produce a significant increase in CL. 
The addition of FN to the final reaction mixture in a concentration of 100 #g/ 
ml, however, resulted in significant enhancement of CL production with each of 
the monoclonal preparations.  Thus,  FN  appeared to  enhance the interaction 
between PMN and bacteria opsonized with monocional IgG, IgM, and, surpris- 
ingly, IgA. HILL  ET  AL.  1623 
We next turned to in vivo protection studies to assess the biologic significance 
of our findings. As shown in Fig. 3, the administration of FN alone (5 mg/kg, 
equivalent to that reported to enhance survival in traumatized, septic humans) 
to neonatal rats infected with type III group B streptococci had no significant 
effect on survival (15%). Similarly, the monoclonal IgG preparation (1.2 mg/kg) 
alone offered little protection (15 %). When both preparations were administered 
together, however, significant protection (60%) was observed (P <  0.0001). FN 
also enhanced the protective efficacy of IglV (data not shown). 
Because  of the  marked  protective  efficacy  of the  IgM  monoclonal,  it  was 
necessary to decrease the dose of this preparation to 0.004 mg/kg to study the 
effects of combined administration with FN. As shown in Fig. 4, the combination 
of the IgM monoclonal and FN also offered significantly enhanced protection 
against type III  group B  streptococcal infection (78%  survival vs.  ~20%; P  < 
0.001).  Monoclonal antibody preparations directed against the group B carbo- 
hydrate or a  nonstreptococcal antigen (TGAL) had no effect on survival when 
administered alone or with FN. 
We were unable to demonstrate significant protection by the IgA monoclonal 
preparation alone in our neonatal rat model (Fig. 5). FN alone failed to provide 
statistically significant protection in these experiments. When both preparations 
were administered together, however, the protection observed was >75%  (P < 
0.001). Thus, the unexpected results obtained in the CL assay, in which IgA and 
FN in combination appeared to promote the interaction of group B streptococci 
with PMN, have a corollary in this in vivo system. 
Electron microscopy studies clearly showed that the combination of FN and 
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FIGURE 5.  Effect of FN and  monoclonal IgA type-specific antibody administration on the 
survival of neonatal rats infected with type III group B streptococci (GBS), Rats received 5 x 
10 6 streptococci,  1.2 mg/kg of IgA monoclonal antibody, and/or 5 mg/kg of FN. 
Ig promoted the ingestion of streptococci by human PMN. In contrast, we were 
unable to demonstrate that FN alone promoted uptake of these organisms; rather 
it appeared that the organisms exposed to PMN  in the presence of FN alone 
were attached to the surface rather than actually being ingested (Fig.  6). 
Discussion 
The present studies indicate that FN enhances the interaction between group 
B streptococci, polyclonal and monoclonal antibody, and phagocytic cells impor- 
tant in host defense against these organisms. FN has been reported (14) to bind 
to Staphylococcus aureus and to promote attachment but not ingestion by phago- 
cytic cells. Myhre and Kuusela (15) have shown that FN also binds to group A, 
C, and G streptococci; group B strains were not studied. Simpson and Beachey 
(16) have indicated that FN serves as the surface receptor for group A strepto- 
cocci on oral epithelial cells. Thus, it is clear that FN plays at least some role in 
the host defense mechanism against gram-positive organisms, and particularly 
streptococci. The present studies are the first to  show that  FN  promotes the 
interaction of group  B  streptococci with  PMN  and polyclonal or monoclonal 
antibody. 
Bevilacqua and associates (2) reported that FN enhances the expression of Fc 
and C3b receptors on the surface of human monocytes. In contrast, Pommier et 
al. (3) could not demonstrate an effect of FN on the expression of Fc receptors 
on monocytes, results which are similar to ours using PMN. They pointed out, 
however, that receptor number does not appear to correlate with rosette for- 
mation,  tn results similar to ours using group  B streptococci, they found that 
preincubation  of  monocytes  with  FN  increased  their  phagocytic  ability  for 
C3b-, IgG-, and IgM-coated SE.  In addition, we found that the FN also had the 
effect of promoting the interaction of group B streptococci with human PMN 
when combined with a  type-specific IgA  monoclonal preparation.  IgA  is  not 
known  to  promote opsonization  by itself, or in  the presence of complement, HILL ET  AL,  1625 
FIGURE 6.  Light micrograph of human  PMN exposed to unopsonized type lII group  B 
streptococci in the presence of FN. 
under most circumstances. The one exception to this was the report by Lowell 
et al. (17) demonstrating IgA-mediated phagocytosis of Neisseria meningitidis. 
We next turned to a neonatal rat model to ascertain the biological significance 
of the data we had developed with  FN and the various antibody preparations. 
Administration of FN alone did not protect the rats from infection with type III 1626  FIBRONECTIN ENHANCES GROUP B STREPTOCOCCAL ANTIBODY 
group B streptococci. Combined administration of FN with IgIV or the IgG or 
IgM  monoclonal resulted  in  enhanced survival  above  that  with  the antibody 
alone. To our knowledge, this is the first evidence that FN enhances the actual 
protective activity of specific antibody in vivo. It should be pointed out that FN 
had no effect on survival when combined with an anti-group B monoclonal or 
with a nonstreptococcal monoclonal antibody (anti-TGAL). 
Egan and co-workers (7) reported that the IgA monoclonai antibody that we 
used protected mucin-treated adult mice from challenge with type III group B 
streptococci. The IgA monoclonal alone, in contrast, did not protect our neonatal 
rats from type III group B streptococcal infection. When FN was administered 
along with the IgA monoclonal, however, protection was >75%.  It is likely that 
adult mice used in the studies of Egan et al. (7) had normal FN levels. In contrast, 
we (18) and other (19) have found that plasma FN concentrations are significantly 
decreased in neonates. This could explain the differences observed in the two 
studies using the same monoclonal preparation. The striking finding, however, 
was the profound enhancement of protection induced by the administration of 
a combination of FN and the IgA monoclonal antibody. 
Although the exact mechanism of action of FN  in  this and other reported 
studies (1-3,  14-16)  is not known, it is clear that this interesting glycoprotein 
affects  the  interaction  of phagocytic  cells  and  Ig,  resulting  not  only  in  the 
enhancement of particle uptake in vitro, but also in improved survival after in 
vivo bacterial  challenge.  It  may be  that  optimal  immunotherapy of neonatal 
group B streptococcal disease will  involve the administration of both antibody 
and FN. 
Summary 
We have investigated the opsonic and protective effects of fibronectin (FN) 
against type III  group  B  streptococci.  When  used by itself,  the  FN  failed to 
promote actual internalization of group  B  organisms.  The addition of FN  to 
group B streptococci that had been preopsonized in an immunoglobulin prepa- 
ration modified for intravenous use (IgIV) or a type-specific, murine monoclonal 
antibody of IgG isotype markedly enhanced interaction with human polymor- 
phonuclear leukocytes (PMN). A similar enhanced effect was observed when the 
FN was combined with type-specific monoclonal antibody preparations of IgM 
and,  surprisingly,  IgA  isotype.  Preincubation  experiments indicated that  the 
major effect was upon  the PMN  rather than directly on the bacteria,  but we 
could not  demonstrate an  effect of FN  on  cell  surface receptors  for  the  Fc 
fragment of Ig or C3b using rosetting techniques. In addition to enhancing the 
in vitro opsonic activity of Ig, the FN significantly increased the protective effect 
of the polyclonal and monoclonal Ig preparations in an animal model of neonatal 
group B streptococcal disease. Thus,  FN appears to have a  critical role in the 
host defense mechanisms against group B streptococci. 
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